27-08-2020
Sundry Photography / Shutterstock.com
Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel (etanercept).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Sandoz, Immunex, biologics, Federal Circuit, Enbrel, rheumatoid arthritis, patent exclusivity, gamesmanship, Roche
SCOTUS declines patents review on Enbrel drug
18-05-2021
English court resumes Amgen cholesterol patent suit
23-10-2020
Fed Circuit affirms cancellation of Anacor antifungal patents
01-09-2020
Sandoz gains backing for Enbrel patent term review
20-08-2020
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
02-07-2020
